* history of covid-19 disease or prior sars-cov-2 infection confirmed serologically. * known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months). * chronic illness or condition considered to potentially increase the risk for severe covid illness or that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion. * known liver disease or fatty liver. * positive test for chronic active hepatitis b surface antigen, hepatitis b core antibody, hepatitis c antibody, or human immunodeficiency virus (hiv) antibody from blood work collected at screening visit. * bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination based on investigator's judgment. * receipt of immunoglobulins, blood or blood-derived products in the past 3 months. * prior administration of a coronavirus vaccine (sars-cov-2, sars-cov, middle east respiratory syndrome coronavirus \[mers-cov\]). * receipt of any vaccine in the 30 days preceding the first study vaccination or planned receipt of any vaccine in the 30 days following the last study vaccination except for influenza vaccination, which might be received at least 2 weeks before and a minimum of 2 weeks after study vaccines. * receipt of any therapy known to have in-vitro antiviral activity against sars-cov-2 within 72 hours prior to the first blood draw or planned use of such therapy 72 hours prior to study immunogenicity blood draws at day 22 and day 36. * residence in a nursing home or long-term care facility. * health care workers providing direct patient care for covid-19 participants. the above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

* history of covid-19 disease or prior sars-cov-2 infection confirmed serologically. * known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months). * chronic illness or condition considered to potentially increase the risk for severe covid illness or that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion. * known liver disease or fatty liver. * positive test for chronic active hepatitis b surface antigen, hepatitis b core antibody, hepatitis c antibody, or human immunodeficiency virus (hiv) antibody from blood work collected at screening visit. * bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination based on investigator's judgment. * receipt of immunoglobulins, blood or blood-derived products in the past 3 months. * prior administration of a coronavirus vaccine (sars-cov-2, sars-cov, middle east respiratory syndrome coronavirus \[mers-cov\]). * receipt of any vaccine in the 30 days preceding the first study vaccination or planned receipt of any vaccine in the 30 days following the last study vaccination except for influenza vaccination, which might be received at least 2 weeks before and a minimum of 2 weeks after study vaccines. * receipt of any therapy known to have in-vitro antiviral activity against sars-cov-2 within 72 hours prior to the first blood draw or planned use of such therapy 72 hours prior to study immunogenicity blood draws at day 22 and day 36. * residence in a nursing home or long-term care facility. * health care workers providing direct patient care for covid-19 participants. the above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

history of covid-19 disease or prior sars-cov-2 infection confirmed serologically. known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months). chronic illness or condition considered to potentially increase the risk for severe covid illness or that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion. known liver disease or fatty liver. positive test for chronic active hepatitis b surface antigen, hepatitis b core antibody, hepatitis c antibody, or human immunodeficiency virus (hiv) antibody from blood work collected at screening visit. bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination based on investigator's judgment. receipt of immunoglobulins, blood or blood-derived products in the past 3 months. prior administration of a coronavirus vaccine (sars-cov-2, sars-cov, middle east respiratory syndrome coronavirus [mers-cov]). receipt of any vaccine in the 30 days preceding the first study vaccination or planned receipt of any vaccine in the 30 days following the last study vaccination except for influenza vaccination, which might be received at least 2 weeks before and a minimum of 2 weeks after study vaccines. receipt of any therapy known to have in-vitro antiviral activity against sars-cov-2 within 72 hours prior to the first blood draw or planned use of such therapy 72 hours prior to study immunogenicity blood draws at day 22 and day 36. residence in a nursing home or long-term care facility. health care workers providing direct patient care for covid-19 participants. the above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

history of covid-19 disease or prior sars-cov-2 infection confirmed serologically. known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months). chronic illness or condition considered to potentially increase the risk for severe covid illness or that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion. known liver disease or fatty liver. positive test for chronic active hepatitis b surface antigen, hepatitis b core antibody, hepatitis c antibody, or human immunodeficiency virus (hiv) antibody from blood work collected at screening visit. bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination based on investigator's judgment. receipt of immunoglobulins, blood or blood-derived products in the past 3 months. prior administration of a coronavirus vaccine (sars-cov-2, sars-cov, middle east respiratory syndrome coronavirus [mers-cov]). receipt of any vaccine in the 30 days preceding the first study vaccination or planned receipt of any vaccine in the 30 days following the last study vaccination except for influenza vaccination, which might be received at least 2 weeks before and a minimum of 2 weeks after study vaccines. receipt of any therapy known to have in-vitro antiviral activity against sars-cov-2 within 72 hours prior to the first blood draw or planned use of such therapy 72 hours prior to study immunogenicity blood draws at day 22 and day 36. residence in a nursing home or long-term care facility. health care workers providing direct patient care for covid-19 participants. the above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

history of covid-19 disease or prior severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection confirmed serologically. known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months). chronic illness or condition considered to potentially increase the risk for severe covid illness or that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion. known liver disease or fatty liver. positive test for chronic active hepatitis b surface antigen, hepatitis b core antibody, hepatitis c antibody, or human immunodeficiency virus (hiv) antibody from blood work collected at screening visit. bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination based on investigator's judgment. receipt of immuneglobulins, blood or blood-derived products in the past 3 months. prior administration of a coronavirus vaccine (sars-cov-2, sars-cov, middle east respiratory syndrome coronavirus [mers-cov]). receipt of any vaccine in the 30 days preceding the first study vaccination or planned receipt of any vaccine in the 30 days following the last study vaccination except for influenza vaccination, which may be received at least 2 weeks before and a minimum of 2 weeks after study vaccines. receipt of any therapy known to have in-vitro antiviral activity against sars-cov-2 within 72 hours prior to the first blood draw or planned use of such therapy 72 hours prior to study immunogenicity blood draws at day 22 and day 36. residence in a nursing home or long-term care facility. health care workers providing direct patient care for covid-19 participants. the above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

history of covid-19 disease or prior severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection confirmed serologically. known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months). chronic illness or condition considered to potentially increase the risk for severe covid illness or that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion. known liver disease or fatty liver. positive test for chronic active hepatitis b surface antigen, hepatitis b core antibody, hepatitis c antibody, or human immunodeficiency virus (hiv) antibody from blood work collected at screening visit. bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination based on investigator's judgment. receipt of immuneglobulins, blood or blood-derived products in the past 3 months. prior administration of a coronavirus vaccine (sars-cov-2, sars-cov, middle east respiratory syndrome coronavirus [mers-cov]). receipt of any vaccine in the 30 days preceding the first study vaccination or planned receipt of any vaccine in the 30 days following the last study vaccination except for influenza vaccination, which may be received at least 2 weeks before and a minimum of 2 weeks after study vaccines. receipt of any therapy known to have in-vitro antiviral activity against sars-cov-2 within 72 hours prior to the first blood draw or planned use of such therapy 72 hours prior to study immunogenicity blood draws at day 22 and day 36. residence in a nursing home or long-term care facility. health care workers providing direct patient care for covid-19 participants. the above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- history of covid-19 disease or prior severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection confirmed serologically. - known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months). - chronic illness or condition considered to potentially increase the risk for severe covid illness or that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion. - known liver disease or fatty liver. - positive test for chronic active hepatitis b surface antigen, hepatitis b core antibody, hepatitis c antibody, or human immunodeficiency virus (hiv) antibody from blood work collected at screening visit. - bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination based on investigator's judgment. - receipt of immuneglobulins, blood or blood-derived products in the past 3 months. - prior administration of a coronavirus vaccine (sars-cov-2, sars-cov, middle east respiratory syndrome coronavirus [mers-cov]). - receipt of any vaccine in the 30 days preceding the first study vaccination or planned receipt of any vaccine in the 30 days following the last study vaccination except for influenza vaccination, which may be received at least 2 weeks before and a minimum of 2 weeks after study vaccines. - receipt of any therapy known to have in-vitro antiviral activity against sars-cov-2 within 72 hours prior to the first blood draw or planned use of such therapy 72 hours prior to study immunogenicity blood draws at day 22 and day 36. - residence in a nursing home or long-term care facility. - health care workers providing direct patient care for covid-19 patients. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- history of covid-19 disease or prior severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection confirmed serologically. - known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months). - chronic illness or condition considered to potentially increase the risk for severe covid illness or that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion. - known liver disease or fatty liver. - positive test for chronic active hepatitis b surface antigen, hepatitis b core antibody, hepatitis c antibody, or human immunodeficiency virus (hiv) antibody from blood work collected at screening visit. - bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination based on investigator's judgment. - receipt of immuneglobulins, blood or blood-derived products in the past 3 months. - prior administration of a coronavirus vaccine (sars-cov-2, sars-cov, middle east respiratory syndrome coronavirus [mers-cov]). - receipt of any vaccine in the 30 days preceding the first study vaccination or planned receipt of any vaccine in the 30 days following the last study vaccination except for influenza vaccination, which may be received at least 2 weeks before and a minimum of 2 weeks after study vaccines. - receipt of any therapy known to have in-vitro antiviral activity against sars-cov-2 within 72 hours prior to the first blood draw or planned use of such therapy 72 hours prior to study immunogenicity blood draws at day 22 and day 36. - residence in a nursing home or long-term care facility. - health care workers providing direct patient care for covid-19 patients. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.